Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Daniel R. Weinberger" Clear advanced filters
  • A drug that activates glutamate receptors offers promise for a new class of anti-psychotic therapeutics and sheds light on the pathophysiology of this devastating disease (pages 1102–1107).

    • Daniel R Weinberger
    News & Views
    Nature Medicine
    Volume: 13, P: 1018-1019
  • A causal explanation for the pathogenesis of schizophrenia is lacking. In this Review, Birnbaum and Weinberger explore recent genetic studies of schizophrenia and discuss how genetic and epigenetic risk of the disorder may converge to perturb key neurodevelopmental trajectories.

    • Rebecca Birnbaum
    • Daniel R. Weinberger
    Reviews
    Nature Reviews Neuroscience
    Volume: 18, P: 727-740
  • Understanding how the complex molecular mechanisms of the brain can be blighted, and what their role is in neurological disorders, can be an intricate task. The basis of mood alterations and how humans react to a damaged or altered brain circuit can provide clues for new therapies to target the root of these neurological glitches. In 'Bedside to Bench', Daniel Weinberger and Caroline Zink discuss how people with anorexia nervosa showed a connection between self starvation and motivational value—an opposite perspective to the traditional idea linking the absence of joy to the symptoms of this disorder and a new paradigm for developing the appropriate treatments. In 'Bench to Bedside', Dennis Charney and James Murrough peruse how the antidepressant action of ketamine in rats—a neurotrophic effect—can explain the rapid reduction in depression observed in the clinic with this drug. The receptors and signaling cascades involved may be used to develop therapies that may further enhance this rapid beneficial effect.

    • Caroline F Zink
    • Daniel R Weinberger
    Comments & Opinion
    Nature Medicine
    Volume: 16, P: 1382-1383
  • Using schizophrenia as an example, Meyer-Lindenberg and Weinberger review the effectiveness of the intermediate phenotype concept for characterizing the neural systems affected by risk gene variants, with a view to elucidating mechanistic aspects of brain function implicated in psychiatric disease.

    • Andreas Meyer-Lindenberg
    • Daniel R. Weinberger
    Reviews
    Nature Reviews Neuroscience
    Volume: 7, P: 818-827